1,175 Shares in GSK PLC Sponsored ADR (NYSE:GSK) Acquired by CX Institutional

CX Institutional bought a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,175 shares of the pharmaceutical company’s stock, valued at approximately $46,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Integrated Advisors Network LLC lifted its stake in GSK by 6.9% during the first quarter. Integrated Advisors Network LLC now owns 9,714 shares of the pharmaceutical company’s stock worth $376,000 after purchasing an additional 625 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of GSK by 71.4% during the 1st quarter. SG Americas Securities LLC now owns 18,840 shares of the pharmaceutical company’s stock valued at $730,000 after buying an additional 7,849 shares in the last quarter. MADDEN SECURITIES Corp lifted its position in GSK by 22.2% in the 1st quarter. MADDEN SECURITIES Corp now owns 106,830 shares of the pharmaceutical company’s stock worth $4,139,000 after buying an additional 19,400 shares during the last quarter. GAMMA Investing LLC boosted its stake in GSK by 107.8% in the first quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company’s stock worth $172,000 after buying an additional 2,307 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in GSK by 50.1% during the first quarter. Farther Finance Advisors LLC now owns 6,085 shares of the pharmaceutical company’s stock valued at $230,000 after acquiring an additional 2,030 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $39.69 on Wednesday. The company has a 50 day moving average of $38.32 and a 200 day moving average of $36.75. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The firm has a market cap of $81.35 billion, a P/E ratio of 20.46, a PEG ratio of 1.42 and a beta of 0.52.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same period in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.25%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 87.11%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GSK. BNP Paribas began coverage on shares of GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price target for the company. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Hsbc Global Res raised GSK to a “strong sell” rating in a research note on Monday, April 28th. Finally, Berenberg Bank reissued a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.